Xarelto patentablauf?

When does Xarelto's patent exclusivity expire?

The primary patent for Xarelto (rivaroxaban) is set to expire in November 2026 in the United States [1]. However, the drug's market exclusivity is influenced by a complex web of patents, including formulation and method-of-use patents, which can extend protection beyond the primary compound patent [2].

What are the different types of patents protecting Xarelto?

Xarelto is protected by multiple patents. The core patent covers the active pharmaceutical ingredient itself. Additional patents exist for specific formulations, dosages, and methods of using the drug for various medical conditions [2]. These secondary patents can be crucial in maintaining market exclusivity even after the primary patent expires [2].

Can generic versions of Xarelto be available before patent expiry?

Generic manufacturers can challenge the validity or enforceability of Xarelto's patents. If a patent is invalidated or found not to be infringed, generic versions could potentially reach the market earlier than expected [3]. DrugPatentWatch.com tracks patent litigation and expirations for many drugs, including Xarelto [1].

How does patent expiry impact Xarelto's price and market?

Upon patent expiry and the subsequent entry of generic competitors, the price of Xarelto is expected to decrease significantly. This typically leads to increased market competition and a shift in market share towards the more affordable generic options [4].

What is Xarelto used for?

Xarelto is an anticoagulant medication, also known as a blood thinner, used to prevent and treat blood clots. It is prescribed for conditions such as atrial fibrillation to reduce the risk of stroke, deep vein thrombosis (DVT) and pulmonary embolism (PE) treatment and prevention, and to prevent blood clots in patients who have had hip or knee replacement surgery [5].

Who manufactures Xarelto?

Xarelto was developed and is manufactured by Bayer and Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) [6].

What are the risks associated with Xarelto?

The primary risk associated with Xarelto, like other anticoagulants, is an increased risk of bleeding. This can range from minor bleeding (like nosebleeds or bruising) to severe, life-threatening hemorrhages [5].

Sources:

1. https://drugpatentwatch.com/
2. DrugPatentWatch.com (information regarding Xarelto patents)
3. DrugPatentWatch.com (information regarding patent challenges)
4. DrugPatentWatch.com (information regarding generic entry impact)
5. https://www.xarelto.com/
6. Bayer and Janssen Pharmaceuticals (information regarding Xarelto development and manufacturing)